Journal article
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
- Abstract:
-
Backround: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the MAPK pathway is activated in most melanoma, including BRAF-wt. We assessed whether inhibiting this pathway by adding kinase inhibitors trametinib or pazopanib to paclitaxel chemotherapy improved outcomes in patients with advanced BRAF-wt melanoma in a phase II, randomised, open-label trial.
Patients and Methods: P...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
+ National Institute of Health Research
More from this funder
Funding agency for:
Middleton, M
Grant:
G0601617
GSK/Novartis
More from this funder
National Cancer
Research Network
More from this funder
University of Oxford
More from this funder
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Annals of Oncology Journal website
- Volume:
- 30
- Issue:
- 2
- Pages:
- 317–324
- Publication date:
- 2018-11-14
- Acceptance date:
- 2018-10-30
- DOI:
- EISSN:
-
1569-8041
- ISSN:
-
0923-7534
- Source identifiers:
-
942833
Item Description
- Pubs id:
-
pubs:942833
- UUID:
-
uuid:aa8a31a4-139a-4f97-a8f6-792c7a7ffdba
- Local pid:
- pubs:942833
- Deposit date:
- 2018-11-16
Terms of use
- Copyright holder:
- Urbonas, et al
- Copyright date:
- 2018
- Notes:
-
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record